<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01006018</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00015390</org_study_id>
    <nct_id>NCT01006018</nct_id>
  </id_info>
  <brief_title>DPP-4 Inhibition and TZD for DM Prevention</brief_title>
  <acronym>DInT DM</acronym>
  <official_title>DPP-4 Inhibition and Thiazolidinedione for Diabetes Mellitus Prevention (DInT DM Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether treatment with the diabetes medication, Januvia (sitagliptin), with or
      without another diabetes medicine, Actos (pioglitazone), will improve insulin secretion and
      insulin response individuals with Impaired Glucose Tolerance (IGT), a form of prediabetes.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unanticipated delays due to sterilization/stabilization testing of GLP-1.
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Secretion</measure>
    <time_frame>baseline, 6 months, 9 months (after a 3 month washout)</time_frame>
    <description>Not measured as study was prematurely terminated due to unanticipated delays.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Prediabetic State</condition>
  <arm_group>
    <arm_group_label>Sitagliptin + Pioglitazone PLACEBO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth
+ pioglitazone PLACEBO daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin + Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth
+ pioglitazone (TZD) 15 mg daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth
+ pioglitazone (TZD) PLACEBO daily by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin + Pioglitazone PLACEBO</intervention_name>
    <description>Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily</description>
    <arm_group_label>Sitagliptin + Pioglitazone PLACEBO</arm_group_label>
    <other_name>Januvia (sitagliptin)</other_name>
    <other_name>Pioglitazone (Actos)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin + Pioglitazone</intervention_name>
    <description>Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily</description>
    <arm_group_label>Sitagliptin + Pioglitazone</arm_group_label>
    <other_name>Januvia (sitaglitin)</other_name>
    <other_name>Pioglitazone (Actos)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily</description>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>Januvia (sitagliptin) PLACEBO</other_name>
    <other_name>Pioglitazone (Actos) PLACEBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Impaired glucose tolerance (IGT) by oral glucose tolerance test

        Exclusion Criteria:

          -  History of diabetes mellitus

          -  History of congestive heart failure

          -  History of coronary artery disease or other macrovascular disease (stroke, peripheral
             vascular disease)

          -  History of liver disease (ALT or AST &gt;2.5 times the upper limit of normals)

          -  History of renal disease (serum creatinine &gt;1.5 mg/dl)

          -  History of severe osteoporosis (frequent fractures, failure on osteoporosis treatment)

          -  Current treatment with glucocorticoids

          -  History of immune disorder, including HIV

          -  Women of child-bearing age who are pregnant, desire to become pregnant, are
             breastfeeding, or who refuse to take the recommended birth control measures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Rhee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2009</study_first_submitted>
  <study_first_submitted_qc>October 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2009</study_first_posted>
  <results_first_submitted>March 14, 2013</results_first_submitted>
  <results_first_submitted_qc>May 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 7, 2013</results_first_posted>
  <last_update_submitted>November 12, 2013</last_update_submitted>
  <last_update_submitted_qc>November 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Dr. Mary Rhee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Prediabetic State</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Only 3 control (normal glucose tolerance) subjects were enrolled to obtain results in normal subjects for the hyperglycemic clamp (without GLP-1 or arginine). No samples were run, and, therefore, there are no data for the control subjects.
No subjects with impaired glucose tolerance (IGT) were recruited or enrolled in the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin + Pioglitazone PLACEBO</title>
          <description>Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth
+ pioglitazone PLACEBO daily by mouth</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin + Pioglitazone</title>
          <description>Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth
+ pioglitazone (TZD) 15 mg daily by mouth</description>
        </group>
        <group group_id="P3">
          <title>PLACEBO</title>
          <description>Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth
+ pioglitazone (TZD) PLACEBO daily by mouth</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin + Pioglitazone PLACEBO</title>
          <description>Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth
+ pioglitazone PLACEBO daily by mouth</description>
        </group>
        <group group_id="B2">
          <title>Sitagliptin + Pioglitazone</title>
          <description>Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth
+ pioglitazone (TZD) 15 mg daily by mouth</description>
        </group>
        <group group_id="B3">
          <title>PLACEBO</title>
          <description>Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth
+ pioglitazone (TZD) PLACEBO daily by mouth</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Secretion</title>
        <description>Not measured as study was prematurely terminated due to unanticipated delays.</description>
        <time_frame>baseline, 6 months, 9 months (after a 3 month washout)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin + Pioglitazone PLACEBO</title>
            <description>Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth
+ pioglitazone PLACEBO daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin + Pioglitazone</title>
            <description>Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth
+ pioglitazone (TZD) 15 mg daily by mouth</description>
          </group>
          <group group_id="O3">
            <title>PLACEBO</title>
            <description>Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth
+ pioglitazone (TZD) PLACEBO daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Secretion</title>
          <description>Not measured as study was prematurely terminated due to unanticipated delays.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin + Pioglitazone PLACEBO</title>
          <description>Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth
+ pioglitazone PLACEBO daily by mouth</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin + Pioglitazone</title>
          <description>Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth
+ pioglitazone (TZD) 15 mg daily by mouth</description>
        </group>
        <group group_id="E3">
          <title>PLACEBO</title>
          <description>Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth
+ pioglitazone (TZD) PLACEBO daily by mouth</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Rhee, M.D.</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1666</phone>
      <email>mrhee@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

